Medtronic at ESC: Treating hypertension, shrinking enlarged hearts, and confirming long-term DES
Medtronic has been busy during the weekend's European Society of Cardiology Congress, releasing data from 3 studies touting the benefits renal ablation in treatment of hypertension, CRT for shrinking enlarged hearts and long-term use of drug-eluting stents.
Medtronic (NYSE:MDT) unveiled the results of 3 new studies during the weekend's European Society of Cardiology Congress in Munich Germany, touting the company's renal ablation devices, cardiac rhythm therapy systems and drug-eluting stents.
The medical device titan released an 18-month update from its Symplicity trial, reporting continued success for renal ablation in treatment of hypertension.
Medtronic reported that the device continued to provide sustained blood pressure reduction at 18 months, and no new vascular complications were reported for the 12-to-18-month period.